Leman Biotech vs Mabylon
Leman Biotech vs Mabylon, compared side by side on 13 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Leman Biotech is on 48/100 and Mabylon on 35/100.
Where each one leads
Leman Biotech
- our overall score: 48/100 against 35/100
Mabylon
- agent readiness: 30/100 against 20/100
- funding raised: $35.8M against $22.7M
At a glance
| Measure | Leman Biotech | Mabylon |
|---|---|---|
| What it is | Clinical-stage biotech developing AI-driven metabolic immunotherapies for cancer and autoimmune diseases. | Mabylon is a biotechnology company focused on developing innovative antibody-based therapies for infectious diseases and cancer. |
| Category | Biotech, HealthTech, Drug Discovery, Immunotherapy | Biotech, MedTech, Drug Discovery, Antibody Therapeutics |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Platform |
| Founded | 2021 | Not published |
| Headquarters | Shenzhen, China | Geneva, Switzerland |
| Status | Inactive | Active |
Size, funding and growth
| Measure | Leman Biotech | Mabylon |
|---|---|---|
| Total funding | $22.7M | $35.8M |
| Latest round | Series A | Series A |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Leman Biotech | Mabylon |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 48/100 | 35/100 |
| Traction | 37/100 | 38/100 |
| Team | 60/100 | Not published |
| Search visibility | 18/100 | 2/100 |
| Quality | 58/100 | 45/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (20/100) | F (30/100) |
| Domain ratingLink authority, 0-100 | Not published | 32/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Leman Biotech | Mabylon |
|---|---|---|
| Hosting | Not detected | Self Managed |
| Frameworks | Not detected | Jquery, Bootstrap |
| Analytics | Not detected | Google Analytics 4 |
Leman Biotech vs Mabylon: common questions
Which is better, Leman Biotech or Mabylon?
On our 0-100 score Leman Biotech rates higher (48/100 against 35/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 13 data points above: read the rows that match what you are buying for.
How do Leman Biotech and Mabylon compare on the numbers?
Leman Biotech leads on our overall score (48/100 against 35/100). Mabylon leads on agent readiness (30/100 against 20/100), funding raised ($35.8M against $22.7M).
Read the full Leman Biotech review and pricing or the Mabylon review and pricing. You can also browse other Leman Biotech alternatives we track.